15 results about "Synthetic antigen" patented technology

The invention relates to the technical field of vaccines, and discloses a preparation method and application of an anti-tumor vaccine based on an autoantigen and a synthetic antigen. The anti-tumor vaccine comprises a tumor autoantigen and a synthetic antigen, wherein the tumor autoantigen is extracted from a tumor cell membrane, a tumor cell lysate, a tumor cell secretion, an exosome antigen or an antigen released by a tumor microenvironment; the synthetic antigen is selected from at least one of a tumor associated antigen, a tumor specific antigen, a personalized neoantigen, a pathogen antigen, a biotoxin, a biomolecule antigen and coding nucleic acid of a peptide type antigen in the antigens; the coding nucleic acid is DNA or mRNA. The vaccine molecule composed of the tumor autoantigen and the synthetic antigen is easy to prepare, has a strong anti-tumor immune effect and good biological safety, solves the problems that the traditional tumor autoantigen has no specific precise target spot and the synthetic antigen is single in immunogen, and has a wide application prospect.

The invention belongs to the technical field of biological medicine and disease prevention and treatment, and particularly relates to an SSEA4 conjugated virus-like particle anti-cancer vaccine as well as a preparation method and application thereof. Specifically, according to the vaccine, an SSEA4 antigen is efficiently synthesized through a chemical enzyme method, then the SSEA4 antigen is covalently coupled with a virus-like particle (VLP), the SSEA4 antigen and the VLP are combined with a monophosphoryl lipid A adjuvant with high safety, an organism can be induced to generate strong and lasting SSEA4-resistant humoral immune response, the generated antibody can specifically recognize and kill SSEA4 positive tumor cells, and the SSEA4 positive tumor cells can be effectively killed. Meanwhile, good safety is shown in an animal model, a new solution is provided for immunotherapy of SSEA4 positive tumors, and therefore the SSEA4 positive tumor immunotherapy polypeptide has wide application prospects and market value.

The application provides novel peptide epitope tags and recombinant polynucleotide, polypeptides, vectors, cells and compositions comprising the tags. The application also provides novel designs for synthetic antigen receptors (SARs), novel antigen binding domains, novel SAR constructs and novel methods for manufacturing of cell therapy products. These novel methods and compositions have broad uses in cellular therapy.

The present inventors have identified a combination vaccine for immunization against bacterial meningitis caused by multiple pathogens.

This application provides novel viral envelope glycoproteins for pseudotyping viral vectors, novel designs of synthetic antigen receptors (SARs), novel signaling chains for constructing SARs, novel antigen-binding domains, and novel methods for producing SAR-expressing cells. These novel methods and compositions are widely used in cell therapy.

The application provides novel peptide epitope tags and recombinant polynucleotide, polypeptides, vectors, cells and compositions comprising the tags. The application also provides novel designs for synthetic antigen receptors (SARs), novel antigen binding domains, novel SAR constructs and novel methods for manufacturing of cell therapy products. These novel methods and compositions have broad uses in cellular therapy.

The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype 1a, 1b, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.

Provided herein are methods for preparing and characterizing SARS-cov2 antigen specific immune cell cultures and preparations and methods of using the same in adoptive immunotherapy for cancer, infections, and immune disorders. Also provided are compositions and methods for generating immune calls expressing synthetic antigen binding receptors targeting SARS-cov2 and methods of use of these cells for the treatment and prevention of COVID-19. Also provided are compositions and methods for determining immune response to SARS-cov2 in a subject, detecting SARS-cov2, measuring cytotoxicity induced by SARS-cov2, and detecting the expression and cytotoxicity of synthetic antigen binding receptors targeting SARS-cov2.

Presented herein are techniques for computer simulation design of customized, engineered antigens. Specifically, in certain embodiments, the methods and systems of the present disclosure provide for engineering antigens to reduce its activation to memory immune responses, such as B-cell and / or T-cell based responses, when introduced into a subject. For example, antigens designed in this manner can improve their performance as vaccinating immunogenic compositions. For example, unwanted to be bound by any particular theory, it is believed, among other things, that a reduction in the degree of triggering a memory immune response may result in an increased production of new antibodies that are selectively tailored by the subject's immune system to neutralize particular (e.g., occurring) epitopes of reference antigens.

The disclosure provides single-chain and multi-chain synthetic antigen receptors, methods of making such synthetic antigen receptors and uses thereof for the treatment of diseases and disorder.

The present application provides novel viral envelope glycoproteins for viral vector pseudotyping, novel designs for synthetic antigen receptors (SARs), novel signal chains for constructing SAR, novel antigen binding domains, and novel methods for generating SAR expressing cells. These novel methods and compositions have broad applications in cell therapy.

Presented herein are technologies directed to in-silico design of custom, engineered, antigens. In particular, in certain embodiments, methods and system of the present disclosure provide for engineering antigens to reduce their activation of a memory immune response, such as B cell and / or T cell based response, when introduced into a subject. Designing antigens in this manner, may, for example, improve their performance as immunogenic compositions for purposes of vaccination. For example, without wishing to be bound to any particular theory, it is believed that, among other things, reducing the extent to which a memory immune response is triggered can lead to improved production of new antibodies that are selectively tailored by the subject's immune system to neutralize particular (e.g., arisen) epitopes of a reference antigen.

The application provides novel peptide epitope tags and recombinant polynucleotide, polypeptides, vectors, cells and compositions comprising the tags. The application also provides novel designs for synthetic antigen receptors (SARs), novel antigen binding domains, novel SAR constructs and novel methods for manufacturing of cell therapy products. These novel methods and compositions have broad uses in cellular therapy.

The present description relates to synthetic antigen receptors for use with covalent immune recruiters (CIRs) comprising an donor moiety, a covalent binding group, and a target binding domain (TBD), the synthetic antigen receptor comprising an extracellular acceptor domain and an effector domain, wherein the extracellular acceptor domain is capable of binding to the donor moiety of the CIR. The present description also includes engineered cells comprising the synthetic antigen receptors, methods and uses thereof, for example, for recognition of target cells by immune cells comprising the synthetic antigen receptor functionalized with a CIR.

The invention belongs to the field of salicylic acid detection, and particularly relates to a salicylic acid chemiluminescence immunoassay kit as well as preparation and application thereof. The kit provided by the invention comprises an R1 reagent (1-3 [mu] m carboxyl magnetic bead coated salicylic acid antibody, a magnetic bead preservation buffer solution containing glycine and bovine serum albumin) and an R2 reagent (alkaline phosphatase coupled salicylic acid synthetic antigen, and an enzyme working solution containing mouse IgG and MgCl2), and by combining a flow injection technology, the detection sensitivity of the kit is improved. The problems that no special kit exists in the existing salicylic acid detection, the high performance liquid chromatography is high in cost, and the spectrophotometric method is poor in sensitivity are effectively solved. The kit provided by the invention can be stably stored for 1 year at 4 DEG C, the deviation between the detection result and the high performance liquid chromatography is less than + / -1%, 60 samples can be detected per hour, the cost is low, the operation is simple and convenient, and the kit is suitable for primary medical institutions and large sample detection.